XenoPort, Inc. To Present New Data For Novel Fumarate Analog XP23829 And HORIZANT at the 66th Annual Meeting Of The American Academy of Neurology
Published: Apr 24, 2014
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present data on its investigational and marketed therapies for neurological diseases at the 66th Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829, an investigational prodrug of monomethyl fumarate (MMF). XP23829 is currently being evaluated as a potential treatment for moderate-to-severe chronic plaque type psoriasis and may be a potential treatment for relapsing forms of multiple sclerosis (MS).
Help employers find you! Check out all the jobs and post your resume.